Loading clinical trials...

Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors | Clinical Trials | Clareo Health

COMPLETED

Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors

Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors - a Prospective Observational Study

NCT05544292•Diakonhjemmet Hospital

View on ClinicalTrials.gov

Summary

RIMRA is a prospective, longitudinal, observational study including patients with de novo symptoms of rheumatic disease or a flare of established rheumatic disease after treatment with an immune check point inhibitor. The aim of the study is to describe the clinical presentation, disease course and outcome of rheumatic irAEs in patients treated with immune check point inhibitors.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•De novo symptoms of rheumatic disease or a flare of established rheumatic disease after \>/= 1 dose of treatment with an immune check point inhibitor
•Adult patients (\> 18 years)
•Subject capable of understanding and signing an informed consent form

Exclusion Criteria

•Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult

Locations (5)

Ålesund Hospital

Ålesund, Norway

Hospital of Southern Norway Trust

Kristiansand, Norway

Levanger Hospital

Levanger, Norway

Diakonhjemmet Hospital

Oslo, Norway

University Hospital of North Norway

Tromsø, Norway

Key Dates

Start Date

March 5, 2018

Primary Completion Date

December 31, 2024

Completion Date

December 31, 2024

Last Updated

August 24, 2025

Enrollment

ACTUAL participants

Conditions

Immune-related Adverse Event

Interventions

Antiinflammatory/DMARDs

OTHER

Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

NCT07453342

Immune-Related Adverse Events

View study

RECRUITINGNA

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

NCT05813418

ImmunotherapyImmune Checkpoint Inhibitors+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors

Inclusion Criteria

Exclusion Criteria

Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

Food Intervention to Reduce Immunotherapy ToXicity

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis